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Research into the cell biology of intracellular pathogens
has provided information on host-pathogen interactions
and on the importance of lipids at various stages in the
interactions. Lipids are “gatekeepers” in important che-
mical reactions involving cell signaling during pathogen
docking, invasion and traffic in and out of cells. Work-
ing with the Novartis Institute for Tropical Diseases,
our team is exploring how TB takes advantage of nor-
mal cellular processes by using its own lipids to subvert
the host’s lipid signaling - allowing it to enter the host
cell and survive there. Our focus is on developing host
and pathogen biomarkers that correlate with TB infec-
tion in laboratory animals and in humans. We are per-
forming mass spectrometry-based multi-marker
quantification of lipids in tissue and body fluids (blood,
urine, sputum), specifically host lipids (e.g. phospholi-
pids and ceramides) and pathogen-derived lipids (e.g.
mycolates, LAM, etc.). Our research is focused on
laboratory animals and TB patients in clinical trials, to
b eu s e db o t hf o rd r u ge f f i c a c ys t u d i e sa sw e l la sc a s e
detection and monitoring of treatment response. For
analysis of the host response, lipids are extracted from
infected tissues and cells, isolated and analyzed by mass
spectrometry to develop a lipid profile, which is used to
identify the metabolic pathways involved in the infection
and the enzyme/protein that facilitates the process. This
technique is very sensitive - a drop of blood is poten-
tially enough to perform the analysis. For pathogen bio-
marker discovery, mycobacterial lipids are isolated
directly from small volumes of infected body fluids such
as sputum and subsequently quantified via mass spec-
trometry. We expect this research will be (i) useful in
providing a better description of mycobacterial bios-
ynthetic activity, which will be helpful in developing
new diagnostics, drugs and vaccines, and (ii) for the
development of lipid biomarker for TB case detection.
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